ALX Oncology (ALXO) Scheduled to Post Quarterly Earnings on Thursday

ALX Oncology (NASDAQ:ALXO) is scheduled to post its quarterly earnings results on Thursday, March 7th.

ALX Oncology Price Performance

NASDAQ:ALXO traded up $0.01 during trading hours on Wednesday, reaching $14.78. 239,073 shares of the stock were exchanged, compared to its average volume of 321,023. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.42. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $14.73 and a 200-day simple moving average of $10.26.

Insider Activity

In related news, CAO Shelly Pinto sold 2,717 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $13.60, for a total value of $36,951.20. Following the completion of the transaction, the chief accounting officer now owns 78,591 shares of the company’s stock, valued at approximately $1,068,837.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 50.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On ALX Oncology

Several hedge funds have recently bought and sold shares of ALXO. Legal & General Group Plc grew its holdings in shares of ALX Oncology by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after acquiring an additional 684 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of ALX Oncology by 226.6% during the second quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock worth $30,000 after acquiring an additional 2,776 shares during the period. Quantbot Technologies LP raised its holdings in shares of ALX Oncology by 338.3% in the 1st quarter. Quantbot Technologies LP now owns 7,100 shares of the company’s stock valued at $119,000 after purchasing an additional 5,480 shares during the period. Citigroup Inc. grew its stake in ALX Oncology by 671.8% in the 2nd quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock valued at $54,000 after buying an additional 6,214 shares during the last quarter. Finally, UBS Group AG bought a new stake in shares of ALX Oncology in the fourth quarter valued at approximately $82,000. 83.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ALXO shares. Stifel Nicolaus cut their price target on ALX Oncology from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and boosted their price target for the stock from $8.00 to $18.00 in a research report on Friday, December 8th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $20.07.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.